A phase I dose-escalation study of MEDI-575, a PDGFRα monoclonal antibody, in adults with advanced solid tumors.

Authors

C R. Becerra
P Conkling
N Vogelzang
H Wu
S Hong
R Narwal
M Liang
F Tavakkoli
Naushira Pandya, Nova Southeastern UniversityFollow

Publication Title

Cancer chemotherapy and pharmacology

ISSN

0344-5704

Publication Date

11-1-2014

DOI

10.1007/s00280-014-2567-9

Volume

74

Issue

5

First Page

917

Last Page

25

Disciplines

Medical Specialties | Medicine and Health Sciences | Osteopathic Medicine and Osteopathy

NSUWorks Citation

Becerra, C R.; Conkling, P; Vogelzang, N; Wu, H; Hong, S; Narwal, R; Liang, M; Tavakkoli, F; and Pandya, Naushira, "A phase I dose-escalation study of MEDI-575, a PDGFRα monoclonal antibody, in adults with advanced solid tumors." (2014). Faculty Articles. 536.
https://nsuworks.nova.edu/hpd_com_faculty_articles/536